Literature DB >> 19181263

Synthesis and characterization of [76Br]-labeled high-affinity A3 adenosine receptor ligands for positron emission tomography.

Dale O Kiesewetter1, Lixin Lang, Ying Ma, Abesh Kumar Bhattacharjee, Zhan-Guo Gao, Bhalchandra V Joshi, Artem Melman, Sonia de Castro, Kenneth A Jacobson.   

Abstract

INTRODUCTION: Bromine-76-radiolabeled analogues of previously reported high-affinity A(3) adenosine receptor (A(3)AR) nucleoside ligands have been prepared as potential radiotracers for positron emission tomography. <br> METHODS: The radiosyntheses were accomplished by oxidative radiobromination on the N(6)-benzyl moiety of trimethyltin precursors. Biodistribution studies of the kinetics of uptake were conducted in awake rats. <br> RESULTS: We prepared an agonist ligand {[(76)Br](1'S,2'R,3'S,4'R,5'S)-4'-{2-chloro-6-[(3-bromophenylmethyl)amino]purin-9-yl}-1'-(methylaminocarbonyl)bicyclo[3.1.0]hexane-2',3'-diol (MRS3581)} in 59% radiochemical yield with a specific activity of 19.5 GBq/micromol and an antagonist ligand {[(76)Br](1'R,2'R,3'S,4'R,5'S)-4'-(6-(3-bromobenzylamino)-2-chloro-9H-purin-9-yl)bicyclo[3.1.0]hexane-2',3'-diol (MRS5147)} in 65% radiochemical yield with a specific activity of 22 GBq/micromol. The resultant products exhibited the expected high affinity (K(i) approximately 0.6 nM) and specific binding at the human A(3)AR in vitro. Biodistribution studies in the rat showed uptake in the organs of excretion and metabolism. The antagonist MRS5147 exhibited increasing uptake in testes, an organ that contains significant quantities of A(3)AR, over a 2-h time course, which suggests the presence of a specific A(3)AR retention mechanism. <br> CONCLUSION: We were able to compare uptake of the [(76)Br]-labeled antagonist MRS5147 to [(76)Br]agonist MRS3581. The antagonist MRS5147 shows increasing uptake in the testes, an A(3)AR-rich tissue, suggesting that this ligand may have promise as a molecular imaging agent.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19181263      PMCID: PMC2713098          DOI: 10.1016/j.nucmedbio.2008.10.003

Source DB:  PubMed          Journal:  Nucl Med Biol        ISSN: 0969-8051            Impact factor:   2.408


  35 in total

Review 1.  Structure and function of adenosine receptors and their genes.

Authors:  B B Fredholm; G Arslan; L Halldner; B Kull; G Schulte; W Wasserman
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2000-11       Impact factor: 3.000

2.  Agonists to the A3 adenosine receptor induce G-CSF production via NF-kappaB activation: a new class of myeloprotective agents.

Authors:  Sara Bar-Yehuda; Lea Madi; Dana Barak; Moshe Mittelman; Eti Ardon; Avivit Ochaion; Shira Cohn; Pnina Fishman
Journal:  Exp Hematol       Date:  2002-12       Impact factor: 3.084

3.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Authors:  M M Bradford
Journal:  Anal Biochem       Date:  1976-05-07       Impact factor: 3.365

4.  Structure-activity relationships of N6-benzyladenosine-5'-uronamides as A3-selective adenosine agonists.

Authors:  C Gallo-Rodriguez; X D Ji; N Melman; B D Siegman; L H Sanders; J Orlina; B Fischer; Q Pu; M E Olah; P J van Galen
Journal:  J Med Chem       Date:  1994-03-04       Impact factor: 7.446

5.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.

Authors:  Y Cheng; W H Prusoff
Journal:  Biochem Pharmacol       Date:  1973-12-01       Impact factor: 5.858

Review 6.  Pharmacology and therapeutic applications of A3 receptor subtype.

Authors:  Pnina Fishman; Sara Bar-Yehuda
Journal:  Curr Top Med Chem       Date:  2003       Impact factor: 3.295

7.  The A3 adenosine receptor is highly expressed in tumor versus normal cells: potential target for tumor growth inhibition.

Authors:  Lea Madi; Avivit Ochaion; Lea Rath-Wolfson; Sara Bar-Yehuda; Abigail Erlanger; Gil Ohana; Arie Harish; Ofer Merimski; Faina Barer; Pnina Fishman
Journal:  Clin Cancer Res       Date:  2004-07-01       Impact factor: 12.531

8.  Elevated expression of A3 adenosine receptors in human colorectal cancer is reflected in peripheral blood cells.

Authors:  Stefania Gessi; Elena Cattabriga; Arianna Avitabile; Roberta Gafa'; Giovanni Lanza; Luigi Cavazzini; Nicoletta Bianchi; Roberto Gambari; Carlo Feo; Alberto Liboni; Sergio Gullini; Edward Leung; Stephen Mac-Lennan; Pier Andrea Borea
Journal:  Clin Cancer Res       Date:  2004-09-01       Impact factor: 12.531

9.  An agonist to the A3 adenosine receptor inhibits colon carcinoma growth in mice via modulation of GSK-3 beta and NF-kappa B.

Authors:  Pnina Fishman; Sara Bar-Yehuda; Gil Ohana; Faina Barer; Avivit Ochaion; Abigail Erlanger; Lea Madi
Journal:  Oncogene       Date:  2004-04-01       Impact factor: 9.867

10.  Structural determinants of A(3) adenosine receptor activation: nucleoside ligands at the agonist/antagonist boundary.

Authors:  Zhan-Guo Gao; Soo-Kyung Kim; Thibaud Biadatti; Wangzhong Chen; Kyeong Lee; Dov Barak; Seong Gon Kim; Carl R Johnson; Kenneth A Jacobson
Journal:  J Med Chem       Date:  2002-09-26       Impact factor: 8.039

View more
  14 in total

Review 1.  Recent developments in adenosine receptor ligands and their potential as novel drugs.

Authors:  Christa E Müller; Kenneth A Jacobson
Journal:  Biochim Biophys Acta       Date:  2010-12-23

2.  Functionalized congeners of A3 adenosine receptor-selective nucleosides containing a bicyclo[3.1.0]hexane ring system.

Authors:  Dilip K Tosh; Moshe Chinn; Andrei A Ivanov; Athena M Klutz; Zhan-Guo Gao; Kenneth A Jacobson
Journal:  J Med Chem       Date:  2009-12-10       Impact factor: 7.446

Review 3.  Introduction to adenosine receptors as therapeutic targets.

Authors:  Kenneth A Jacobson
Journal:  Handb Exp Pharmacol       Date:  2009

4.  Methanocarba ring as a ribose modification in ligands of G protein-coupled purine and pyrimidine receptors: synthetic approaches.

Authors:  Dilip K Tosh; Kenneth A Jacobson
Journal:  Medchemcomm       Date:  2013-12-17       Impact factor: 3.597

5.  Structure-guided design of A(3) adenosine receptor-selective nucleosides: combination of 2-arylethynyl and bicyclo[3.1.0]hexane substitutions.

Authors:  Dilip K Tosh; Francesca Deflorian; Khai Phan; Zhan-Guo Gao; Tina C Wan; Elizabeth Gizewski; John A Auchampach; Kenneth A Jacobson
Journal:  J Med Chem       Date:  2012-05-16       Impact factor: 7.446

Review 6.  A3 Adenosine Receptors as Modulators of Inflammation: From Medicinal Chemistry to Therapy.

Authors:  Kenneth A Jacobson; Stefania Merighi; Katia Varani; Pier Andrea Borea; Stefania Baraldi; Mojgan Aghazadeh Tabrizi; Romeo Romagnoli; Pier Giovanni Baraldi; Antonella Ciancetta; Dilip K Tosh; Zhan-Guo Gao; Stefania Gessi
Journal:  Med Res Rev       Date:  2017-07-06       Impact factor: 12.944

7.  Click modification in the N6 region of A3 adenosine receptor-selective carbocyclic nucleosides for dendrimeric tethering that preserves pharmacophore recognition.

Authors:  Dilip K Tosh; Khai Phan; Francesca Deflorian; Qiang Wei; Lena S Yoo; Zhan-Guo Gao; Kenneth A Jacobson
Journal:  Bioconjug Chem       Date:  2012-01-11       Impact factor: 4.774

8.  Synthesis and pharmacological characterization of [(125)I]MRS5127, a high affinity, selective agonist radioligand for the A3 adenosine receptor.

Authors:  John A Auchampach; Elizabeth T Gizewski; Tina C Wan; Sonia de Castro; Garth G Brown; Kenneth A Jacobson
Journal:  Biochem Pharmacol       Date:  2009-11-14       Impact factor: 5.858

Review 9.  John Daly Lecture: Structure-guided Drug Design for Adenosine and P2Y Receptors.

Authors:  Kenneth A Jacobson; Zhan-Guo Gao; Silvia Paoletta; Evgeny Kiselev; Saibal Chakraborty; P Suresh Jayasekara; Ramachandran Balasubramanian; Dilip K Tosh
Journal:  Comput Struct Biotechnol J       Date:  2014-10-16       Impact factor: 7.271

10.  [18F]FE@SUPPY: a suitable PET tracer for the adenosine A3 receptor? An in vivo study in rodents.

Authors:  Daniela Haeusler; Claudia Kuntner; Lukas Nics; Markus Savli; Markus Zeilinger; Thomas Wanek; Panagiotis Karagiannis; Rupert R Lanzenberger; Oliver Langer; Karem Shanab; Helmut Spreitzer; Wolfgang Wadsak; Marcus Hacker; Markus Mitterhauser
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-01-20       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.